Is Bone Biologics Corporation (BBLG) a Buy, Sell, or Hold?
NASDAQ : BBLG
Bone Biologics Corporation — News
$0.88 USD
-$0.01 (-1.12%)
- Volume
- 17.2K
- Average Volume
- 48.41K
- Market Capitalization
- $1.59M
- P/E Ratio
- -0.32
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $4.13
- Year Low
- $0.83
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $16.09
| Source | Headline |
|---|---|
|
Bone Biologics (BBLG) to Announce Earnings on Thursday
Bone Biologics (NASDAQ: BBLG - Get Free Report) will likely be issuing its results before the market opens on Thursday, August 13th. Analysts expect Bone Biologics to announce earnings of ($0.39) per share for the quarter. Bone Biologics (NASDAQ: BBLG - Get Free Report) last released its earnings results on Thursday, May 14th. The company reported ($0.43) defenseworld.net - 2026-08-06 03:11:15 |
|
Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities
BURLINGTON, Mass, July 23, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) ("Bone Biologics" or the "Company"), a developer of orthobiologic products for spine fusion markets, today issued a shareholder update summarizing the Company's progress through the first half of 2026, including its recently completed financing, continued advancement of NB1, its rhNELL-1-based bone graft product candidate, and further validation of its manufacturing and product stability profile. “During the first half of 2026, we strengthened several of the fundamental drivers underlying NB1's development and long-term value proposition: clinical execution, product stability, intellectual property protection and capital visibility,” said Bone Biologics CEO Jeff Frelick. globenewswire.com - 2026-07-23 08:00:00 |
|
Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
$3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds upon the exercise in full of warrants in cash $3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds upon the exercise in full of warrants in cash globenewswire.com - 2026-07-07 20:00:00 |
